How has been the historical performance of Orchid Pharma?

Answer:The historical performance of Orchid Pharma shows a significant improvement in financial metrics over the years, particularly from March 2023 to March 2025.

Breakdown:
Orchid Pharma's net sales have steadily increased from 665.90 Cr in March 2023 to 921.93 Cr in March 2025, reflecting a robust growth trajectory. The total operating income followed a similar trend, rising from 665.90 Cr to 921.93 Cr during the same period. The company's operating profit (PBDIT) also improved significantly, increasing from 103.05 Cr in March 2023 to 144.65 Cr in March 2025, although the operating profit margin slightly decreased from 12.56% to 12.71%. Profit before tax rose from 55.25 Cr to 95.56 Cr, and profit after tax increased from 55.25 Cr to 95.76 Cr, indicating a strong recovery from previous losses. The consolidated net profit showed a remarkable increase from 46.32 Cr in March 2023 to 99.66 Cr in March 2025. On the balance sheet, total assets grew from 1,225.21 Cr to 1,687.91 Cr, while total liabilities increased from 1,225.21 Cr to 1,687.91 Cr, reflecting a balanced growth in both assets and liabilities. Cash flow from operating activities improved, with a net cash inflow of 17.00 Cr in March 2025 compared to a net outflow of 19.00 Cr in March 2024. Overall, Orchid Pharma's financial performance demonstrates a strong recovery and growth in key areas over the past few years.